Prediction of high-risk factor in early-stage lung cancer: micropapillary adenocarcinoma

早期肺癌高危因素预测:微乳头状腺癌

阅读:1

Abstract

OBJECTIVE: To identify independent risk factors for micropapillary adenocarcinoma (MPA) in lung adenocarcinoma, a subtype often associated with poor prognosis, in order to support preoperative risk assessment and treatment planning. METHODS: Patients diagnosed with lung adenocarcinoma were classified into the micropapillary adenocarcinoma (MPA) group or the non-MPA group based on pathological findings. Clinical, pathological, and imaging data were collected for both groups. Patients were followed up through outpatient visits or telephone interviews. The primary outcome was disease-free survival (DFS). Independent risk factors for MPA were identified using univariate and multivariate logistic regression analyses. A preoperative predictive model and corresponding nomogram were developed. The receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value and the Hosmer-Lemeshow test and bootstrap - corrected calibration curves were used to evaluate the model's predictive performance. RESULTS: The recurrence rate was significantly higher in the MPA group compared to the non-MPA group. Independent risk factors for MPA included smoking history, CT-diameter (≥22.5 mm), partially-solid nodule (PSN), solid nodule (SN), lobulation, spiculation, presence of vacuoles, and volume doubling time (VDT) (≤310 days). Guided by the multivariable analysis, we constructed a clinically oriented nomogram to provide an intuitive and practical tool for predicting MPA. The nomogram demonstrated excellent discrimination for predicting MPA, with an area under the ROC curve (AUC) of 0.923. CONCLUSION: MPA predicts worse prognosis. The developed nomogram provides improved stratification of patients and supports informed clinical management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。